Evidence map›Paper›PMID 24419174›Full record

Trial reportHuman vaccines & immunotherapeutics2014

Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.

Koichi Shimizu, Yoshihito Kotera, Atsushi Aruga, Nobuhiro Takeshita, Satoshi Katagiri, Shun-ichi Ariizumi, Yutaka Takahashi, Kenji Yoshitoshi, Ken Takasaki, Masakazu Yamamoto

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Specific immunotherapy in hepatocellular cancer: A systematic review.Journal of gastroenterology and hepatology · 2017
    Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. [The consensus on tertiary prevention of primary liver cancer (2022 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  16. [Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Koichi ShimizuDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Yoshihito KoteraDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Atsushi ArugaDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan; Institute of Advanced Biomedical Engineering and Science; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Nobuhiro TakeshitaDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Satoshi KatagiriDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Shun-ichi AriizumiDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Yutaka TakahashiDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Kenji YoshitoshiDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Ken TakasakiDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Masakazu YamamotoDepartment of Gastroenterological Surgery; Tokyo Women's Medical University; Shinjuku-ku, Tokyo, Japan.
Shinjuku Yamabuki High School · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recurrence rate after surgery in patients with hepatocellular carcinoma (HCC) is very high, while prognosis is quite poor. However, there is no standard treatment to prevent recurrence of HCC after a curative operation. In this study, we investigated the clinical utilization of an autologous tumor lysate-pulsed dendritic cell vaccine plus ex vivo activated T cell transfer (ATVAC) in an adjuvant setting for postoperative HCC as a non-randomized controlled trial. Ninety-four patients with invasive HCC received informed consent information regarding the study, and 42 opted to have the ATVAC after surgery. Their recurrence-free survival (RFS) and overall survival (OS) were measured after 5 years and compared with those of 52 patients who selected to have the curative operation alone. The median RFS and OS were 24.5 months and 97.7 months in the patients receiving adjuvant ATVAC and 12.6 months and 41.0 months in the group receiving surgery alone (P = 0.011 and 0.029). In the treated group, patients with positive delayed-type hypersensitivity (DTH) had a better prognosis (RFS P = 0.019, OS P = 0.025). No adverse events of grade 3 or more were observed. A postoperative dendritic cell vaccine plus activated T cell transfer would be a feasible and effective treatment for preventing recurrence in HCC patients and achieving long-term survival especially in DTH positive patients.

Indexed as

Adoptive TransferAdultAgedAged, 80 and overCancer VaccinesCarcinoma, HepatocellularDendritic CellsFemaleHumansLiver NeoplasmsMaleMiddle AgedNon-Randomized Controlled Trials as TopicPostoperative CareRecurrenceT-LymphocytesCancer Vaccinesadjuvant therapyadoptive transfercancer vaccinedendritic cellhepatocellular carcinomaimmunotherapy

Identifiers

PMID24419174
PMCPMC4896569
OpenAlexW2082075114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.